Moderna to seek full FDA authorization for COVID-19 vaccine, cites 96% efficacy in teens
Moderna Inc. told investors today that is intends to soon file for full Food and Drug Administration approval for its COVID-19 vaccine. Moderna, whose vaccine was authorized for emergency use in December for individuals age 18 and older, said its trial data shows that its vaccine is 96% effective in 12 to 17 year-olds who received at least one injection.
Moderna yesterday announced that its vaccine booster, which remains in a phase 2 clinical trial, showed positive immune response for several COVID-19 variants, including those first discovered in South Africa and Brazil. The booster is intended for administration in patients who already completed the standard, two-dose regimen.
Related News Articles
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Chairperson's File
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers…
Headline
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…